In a second sensitivity analysis that excluded the initial two years of follow-up, the positive ANA association with all-cause mortality was statistically significant in participants who enrolled at age ≥75 years with a history of cancer (HR: 2.64; CI: 1.09, 6.38) and the positive ANA association with CVD mortality was statistically significant in participants who enrolled at age ≥75 years (HR: 1.99; CI: 1.04, 3.78). Here, BTG3 is linked to cancer.